Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
作者信息
Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa B, Lesokhin A, Tan C, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S Z, Mailankody S, Hashmi H
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Blood Cancer J. 2025 Aug 14;15(1):137. doi: 10.1038/s41408-025-01343-4.
Abstract
摘要
Zotero 插件